CTLA4 and non-small cell lung carcinoma: KN046 is currently under phase III trials in combination with carboplatin plus paclitaxel (NCT04474119) as a first-line treatment for squamous NSCLC and in combination with lenvatinib (NCT05001724) for NSCLC after ICI resistance, and is expected to show efficacy and safety as a novel CTLA-4 inhibitor.